Identification of serum β-catenin as a biomarker in patients with HBV-related liver diseases

• DOI: 10.1186/s12967-018-1645-x
• Publication Date: 2018-09-29T02:33:37Z
• Authors: Liang Duan; Qianfan Yang; Jun Yang; Qin Hu; Bo Wang; Pu Li; Weixian Chen
• Keywords: Identification

Substantial evidence indicates that β-catenin is a pivotal regulator contributes to the initiation and development of various types diseases. Recently, can be detected in human serum also reported correlated with several disease progression little research. However, very known about relationship between HBV-related liver disease. Serum levels β-catenin, from 77 patients chronic hepatitis B (CHB), 63 associated cirrhosis (HBLC), 61 hepatocellular carcinoma (HCC), 41 healthy HBV carriers (HHCs) 78 controls (HCs) were measured by ELISA. Correlations viral replication necroinflammation parameters analyzed. The receiver operating characteristic (ROC) curve was used assess discriminating power grade different stages disorders. Human hepatic cell line L02 transfected plasmid, underlying mechanism Chronic HBLC but not HHC or HCC showed significantly higher than HCs. DNA parameters. HBV-infected model elevated phosphorylation at Ser473 Akt (p-Akt), Ser9 GSK3β (p-GSK3β) all which blocked treatment inhibitor LY294002. Additionally, ROC analysis for CHB HHCs, yielded an AUC 0.71 (cutoff value, 42 pg/mL; 95% CI 0.61–0.81) 64.93% sensitivity, 73.17% specificity 69.05% accuracy. infection mainly including HBLC, 0.75 0.67–0.83) 66.43% 75.41% 70.92% enhances expression activating Akt/GSK3β signaling. are load. has potential discriminate phase disorders, particularly predicts HHCs predicting form infection.